ArticleGenes & genomics2026
Comprehensive in silico analysis of Acinetobacter isolates from South Korea reveals genomic diversity, antimicrobial resistance, virulence factors, and evolutionary dynamics.
Article in Genes & genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High-Resolution Genomic Surveillance of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMultidrug-resistant Acinetobacter strains pose a significant threat to healthcare systems and have become a growing concern. A state-of-the-art understanding of this formidable pathogen—including its antibacterial resistance profile, virulence factors, genomic diversity, and evolutionary dynamics—is crucial for implementing effective responses during a pandemic.
objectiveTo explore the genomic diversity, antimicrobial resistance (AMR) profile, virulence factors, and evolutionary trends of multidrug-resistant Acinetobacter isolates collected in South Korea from 2010 to 2022, we conducted a comprehensive in silico analysis of 74 complete genome sequences.
methods74 Acinetobacter complete genomes were annotated using Prokka (v1.14.6), and a pangenome was constructed using Roary (v3.13). The genomes were systematically analyzed for antibiotic resistance genes (ARGs), virulence factor genes (VFGs), mobile genetic elements (MGEs), CRISPR/cas, and prophage using various in silico tools. Multi-locus sequence typing (MLST) was conducted using the Pasteur scheme via the MLST 2.0 web server. To assess genetic diversity, eBURST and whole-genome SNP-based phylogenetic analyses were employed. We performed a targeted analysis of carbapenem-resistant Acinetobacter strains, investigating the relationship between prophages and CRISPR/Cas systems.
resultPan-genome analysis showed an open genome structure (α = 0.4921) in Acinetobacter, indicating ongoing genetic evolution. A total of 77 unique resistance genes, linked to six resistance mechanisms and 21 drug classes, were identified, including blaOXA-23, efflux pumps (AdeIJK, AdeFGH), and carbapenemases. Additionally, 68 virulence factors associated with adherence, biofilm formation, iron uptake, immune evasion, and serum resistance etc. were prevalent. Mobile genetic elements, such as Tn6207, Tn6209, Tn2006, Tn2008, and ISAba1/blaOXA-23 combinations, were identified, suggesting mechanisms for the spread of resistance genes. Seventeen types of prophage were identified, and a low prevalence of CRISPR sequence implies susceptibility to phage predation. The ST2 genotype was dominant, and SNP-based phylogeny showed significant genomic diversity.
conclusionThis study provides a comprehensive understanding of the resistance, virulence, and mobile genetic element profile of Acinetobacter isolates from South Korea, laying the groundwork for future antimicrobial resistance research and intervention strategies, especially the bacteriophage treatment.
Indexed as
Identifiers
41269653What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.